Key Metrics
12.6
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
10 - 15
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
48
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.83
5-Year SI
5-year SI
- N/A 2-year SI
- 0.83 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Hepatology
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
2.38
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Liver cancer
- Overall survival
- Hepatocellular carcinoma
- Clinical trial
- Lenvatinib
- Tumor microenvironment
- Confidence interval
- Pembrolizumab
- Magnetic resonance imaging
- Bevacizumab
- Hazard ratio
- Hepatitis B
- Radiofrequency ablation
- Atezolizumab
- Systemic therapy
- Hepatic arterial infusion chemotherapy
- Tumor grade
- Treatment options
- Sorafenib
- Disease progression
Journal Specifications
| Overview | |
| Publisher | KARGER |
| Language | English |
| Frequency | Bi-monthly |
| Article Processing Charges | EUR 3260 | USD 3770 | CHF 3390 |
| Publication Time | 23 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Eastern & Western Association Liver Tumors |
| Frequency | Bi-monthly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 23 |
| Article Processing Charges | EUR 3260 | USD 3770 | CHF 3390 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Liver Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Erratum
- 11 Apr 24
- Liver Cancer
-
Full paper
Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
- 10 Apr 24
- Liver Cancer
-
Full paper
Letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study’
- 27 Mar 24
- Liver Cancer
-
Full paper
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
- 12 Mar 24
- Liver Cancer
-
Full paper
Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT
- 26 Feb 24
- Liver Cancer
-
Full paper
Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study
- 21 Feb 24
- Liver Cancer
Scite analysis
Powered by scite_
632 articles received 14.2k citations see all
- 409 Supporting
- 13,587 Mentioning
- 79 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 4 Errata
- 0 Expression of Concern
FAQs
How long has Liver Cancer been actively publishing?
Liver Cancer has been in operation since 2012 till date.
What is the publishing frequency of Liver Cancer ?
Liver Cancer published with a Bi-monthly frequency.
How many articles did Liver Cancer publish last years ?
In 2023, Liver Cancer published 68 articles.
What is the eISSN & pISSN for Liver Cancer ?
For Liver Cancer,eISSN is 1664-5553 and pISSN is2235-1795.
What is Citescore for Liver Cancer ?
Citescore for Liver Cancer is 12.6.
What is H index for Liver Cancer ?
H index for Liver Cancer is 48.
What is SNIP score for Liver Cancer ?
SNIP score for Liver Cancer is 2.38.
What is the SJR for Liver Cancer ?
SJR for Liver Cancer is Q1.
Who is the publisher of Liver Cancer ?
KARGER is the publisher of Liver Cancer.